Femara 2.5 mg Tablet
  1. Home
  2. Pharma Products
  3. Novartis India Ltd
  4. Femara 2.5 mg Tablet

Femara 2.5 mg Tablet

Femara 2.5 mg Tablet contains letrozole, an aromatase inhibitor used in the treatment of certain types of breast cancer. It reduces estrogen production, which can help slow the growth of hormone-dependent breast cancer cells. The tablet is taken orally under the supervision of a qualified healthcare professional.

BUY NOW

Category

Femara 2.5 mg contains 2.5 mg of letrozole and is supplied as a film-coated tablet for oral use. It is indicated for adjuvant, extended adjuvant, and advanced breast cancer treatment in appropriate postmenopausal patients, with specific use depending on disease status and prior therapy. The recommended dose is 2.5 mg once daily and it can be taken with or without food. Treatment should be prescribed and monitored by a healthcare professional based on the patient’s clinical condition.

Technical Specification

Specification Details
Active Ingredient Letrozole 2.5 mg
Dosage Form Film-Coated Tablet
Therapeutic Class Aromatase Inhibitor
Main Indication Breast Cancer
Route of Administration Oral
Recommended Dose 2.5 mg Once Daily

Product Also Known As

Femara 2.5 mg, Femara Letrozole 2.5 mg Tablet, Letrozole 2.5 mg Tablet, Letrozole Film-Coated Tablet, Femara Breast Cancer Tablet, Letrozole Aromatase Inhibitor

Related products